Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Corindus, Inc. dba Siemens Healthineers Endovascular Robotics | UNKNOWN |
| KCRI Sp. z o.o. | UNKNOWN |
Not provided
Not provided
Not provided
MulTicenter rEgiStry on RoboticalLy Assisted percutaneous coronary interventions- TESLA registry is a retrospective registry evaluating the safety and efficacy of robotically assisted PCI with the CorPath GRX System (Corindus Vascular, Siemens Healthineers, Germany) in real-world interventional cardiology practice.
R-PCI represents a novel approach to performing PCI with several studies showing high technical success and low complication rates. The CorPath GRX System is the second generation of the CorPath platform, dedicated to advancing robotic-assisted vascular procedures to mitigate the orthopaedic and radiation-related occupational hazards associated with the practice of interventional cardiology.
MulTicenter rEgiStry on RoboticalLy Assisted percutaneous coronary interventions- TESLA registry is a retrospective registry evaluating the safety and efficacy of robotically assisted PCI with the CorPath GRX System (Siemens Healthineers, Germany) in real-world interventional cardiology practice in Europe and Asia.
All patients who underwent R-PCI (defined as completion of at least one procedural step robotically) with the CorPath GRX System and completed one-year follow-up are eligible for recruitment in this registry, if older than 18 years. This study includes patients with either stable coronary artery disease, unstable angina, or acute myocardial infarction (MI).
The Study Investigators expect to enroll at least 700 patients (up to 1000). International centers that performed R-PCI with the CorPath GRX System will be invited to participate in this multicenter study.
Baseline, procedural, and follow-up data will be collected for all cases.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Robotically-Assisted Percutaneous Coronary Intervention | All patients older than 18 years, who underwent R-PCI (defined as completion of at least one procedural step robotically) with the CorPath GRX System (Corindus Vascular) and completed one-year follow-up including patients with either stable coronary artery disease, unstable angina, or acute myocardial infarction (MI). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System | Device | The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. The CorPath GRX System is composed of two units; the first is a bedside unit which consists of the extended robotic arm, robotic drive, and single-use loading cassette, and the second is the remote workstation, which consists of the interventional cockpit and the control console. A key innovation of the CorPath GRX System is the software-based automation of common maneuvers, called technIQ automated movements with the potential to increase procedural success, reduce procedure time, and generally increase user comfort with robotic assistance during PCI. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with clinically successful PCI | Clinical success, defined as angiographic success (residual stenosis after stenting of <30% with final TIMI [Thrombolysis In Myocardial Infarction] flow grade 3) without an in-hospital major adverse cardiovascular event (MACE) (death, target vessel MI, or need of repeat target vessel revascularization); | From time of procedure until date of first event or death from any cause, which came first, assessed up to the time of discharge in the index hospitalization |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with ischemia-driven target lesion revascularization (TLR) | Ischemia-driven target lesion revascularization (TLR), at 1 year defined according to the Academic Research Consortium (ARC) criteria; | 1 year post-procedure |
| Number of participants with target lesion failure (TLF) |
| Measure | Description | Time Frame |
|---|---|---|
| Major adverse cardiovascular events (MACE) | In-hospital MACE, the composite of death, target vessel MI, or need of repeat target vessel revascularization; | From time of procedure until date of first event or death from any cause, which came first, assessed up to the time of discharge in the index hospitalization |
Inclusion Criteria:
Exclusion Criteria:
- Unwillingness to provide informed consent (only if applicable).
Not provided
Not provided
Not provided
This registry will include at least 700 patients (up to 1000) who underwent R-PCI. All the international centers that have already utilized the CorPath GRX System have been invited to participate in this multicenter study. The final number of patients enrolled in the study will depend on the final number of participating centers and the number of patients treated with R-PCI with CorPath GRX System in each center. All patients who underwent R-PCI (defined as completion of at least one procedural step robotically) with the CorPath GRX System (Corindus Vascular) and completed one-year follow-up are eligible for recruitment in this registry, if older than 18 years. This study includes patients with either stable coronary artery disease, unstable angina, or acute myocardial infarction (MI).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Adriana Zlahoda-Huzior, MSc | Contact | +48788624993 | azlahoda@carint.pl |
| Name | Affiliation | Role |
|---|---|---|
| Dariusz Dudek, MD, PhD | Clinical Research Center Intercard | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hartcentrum OLV Aalst | Completed | Aalst | Belgium | |||
| SEGEBERGER Kliniken GmbH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
Target lesion failure (TLF) at 1 year, the composite of ARC-defined cardiac death, target vessel MI, or ischemia-driven TLR; |
| 1 year post-procedure |
| Number of participants with target vessel failure (TVF) | Target vessel failure (TVF) at 1 year, the composite of ARC-defined cardiac death, target vessel MI, or ischemia-driven TVR. | 1 year post-procedure |
| Procedure time | The time recorded from initial guidewire insertion into the robotic drive until guide catheter disengagement. | During the procedure |
| Contrast volume | The total contrast volume used during the procedure. | During the procedure |
| Patient radiation exposure | Dose-area-product (DAP) as recorded during the procedure. | During the procedure |
| Number of participants with stent thrombosis |
Stent thrombosis at 1 year, defined according to the ARC criteria; |
| 1 year post-procedure |
| Bleeding events | Bleeding events at 1 year, defined according to the Bleeding ARC (BARC). | 1 year post-procedure |
| Manual input and/or conversion | The incidence and reasons for manual input and/or conversion during R-PCI. | During the procedure |
| Completed |
| Bad Segeberg |
| Germany |
| Universitätsklinikum Freiburg | Completed | Freiburg im Breisgau | Germany |
| Sapporo Cardiovascular Clinic | Completed | Sapporo | Japan |
| Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii | Recruiting | Nowy Sącz | Malopolska | 33-300 | Poland |
|
| Hospital Gregorio Maranon | Completed | Madrid | Spain |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |